References
- Bassil S, Godin P A, Stallaert S, et al. Ovarian hyperstimulation syndrome: a review. Assist Reprod Rev 1995; 5: 90–5
- Golan A, Ron-El R, Herman A, et al. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv 1989; 44: 430–40
- Rizk B, Aboulghar M, Smitz J, et al. The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome. Hum Reprod Update 1997; 3: 255–66
- McClure N, Healy D L, Rogers PAW, et al. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 1994; 344: 235–6
- Neulen J, Yan Z, Raczek S, et al. Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 1995; 6: 1967–71
- Artini P G, Fasciani A, Monti M, et al. Changes in vascular endothelial growth factor levels and the risk of ovarian hyperstimulation syndrome (OHSS) in women enrolled in an in vitro fertilization program. Fertil Steril 1998; 70: 560–4
- Abramov Y, Barak V, Nisman B, et al. Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome. Fertil Steril 1997; 67: 261–5
- Ludwig M, Bauer O, Lopens A, et al. Serum concentration of vascular endothelial growth factor cannot predict the course of severe ovarian hyperstimulation syndrome. Hum Reprod 1998; 13: 30–2
- Navot D, Bergh P A, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 1992; 58: 249–61
- Orvieto R, Ben Rafael Z. The role of the immune system in severe ovarian hyperstimulation syndrome. Med Hypoth 1995; 45: 231–4
- Lewit N, Kol S, Ronen N, et al. Does intravenous administration of human albumin prevent severe ovarian hyperstimulation syndrome?. Fertil Steril 1996; 66: 654–6
- Forman R G, Frydman R, Egan D, et al. Severe ovarian hyperstimulation syndrome using agonists of gonadotropin-releasing hormone for in vitro fertilization: a European series and a proposal for prevention. Fertil Steril 1990; 53: 502–9
- Sher G, Salem R, Feinman M, et al. Eliminating the risk of life-endangering complications following overstimulation with menotropin fertility agents: a report on women undergoing in vitro fertilization and embryo transfer. Obset Gynecol 1993; 81: 1009–10
- Amso N N, Ahuja K K, Morris N, et al. The management of predicted ovarian hyperstimulation involving gonadotropin-releasing hormone analogue with elective cryopreservation of all pre-embryos. Fertil Steril 1990; 53: 1087–90
- Araujo E, Bernardini L, Frederick J L, et al. Prospective randomized human chorionic gonadotropin versus intramuscular progesterone for luteal-phase support in assisted reproduction. J Assist Reprod Genet 1995; 11: 74–8
- Segal S, Casper R F. Gonadotrophin-releasing hormone agonist versus human chorionic gonadotrophin for triggering follicular maturation in vitro fertilization. Fertil Steril 1992; 57: 1254–8
- Orvieto R, Voliovitch I, Fishman P, et al. Interleukin-2 and ovarian hyperstimulation syndrome: a pilot study. Hum Reprod 1995; 1: 24–7
- Artini P G, Monti M, Fasciani A, et al. Correlation between the amount of FSH administered and plasma and follicular fluid VEGF concentrations in women undergoing IVF-ET. Gynecol Endocrinol 1998; 12: 243–7
- Yan Z, Weich H A, Bernart W, et al. Vascular endothelial growth factor (VEGF) messenger ribonucleic acid (mRNA) expression in luteinized human granulosa cells in vitro. J Clin Endocrinol Metab 1993; 77: 1723–5
- Leung D W, Cachianes G, Kuang W J, et al. Vascular endothelial growth factor as a secreted angiogenic mitogen. Science 1989; 246: 1306–9